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Abstract
Background
With one million new cases of colorectal cancer (CRC) diagnosed annually in the world,
CRC is the third most commonly diagnosed cancer in the Western world. Patients with
stage I-III CRC can be cured with surgery but are at risk for recurrence. Colorectal cancer is
characterized by the presence of chromosomal deletions and gains. Large genomic profil-
ing studies have however not been conducted in this disease. The number of a specific
genetic aberration in a tumour sample could correlate with recurrence-free survival or over-
all survival, possibly leading to its use as biomarker for therapeutic decisions. At this point
there are not sufficient markers for prediction of disease recurrence in colorectal cancer,
which can be used in the clinic to discriminate between stage II patients who will benefit
from adjuvant chemotherapy. For instance, the benefit of adjuvant chemotherapy has been
most clearly demonstrated in stage III disease with an approximately 30 percent relative
reduction in the risk of disease recurrence. The benefits of adjuvant chemotherapy in stage
II disease are less certain, the risk for relapse is much smaller in the overall group and the
specific patients at risk are hard to identify.
Materials and Methods
In this study, array-comparative genomic hybridization analysis (array-CGH) was applied to
study high-resolution DNA copy number alterations in 93 colon carcinoma samples. These
genomic data were combined with parameters like KRASmutation status, microsatellite sta-
tus and clinicopathological characteristics.
Results
Both large and small chromosomal losses and gains were identified in our sample cohort.
Recurrent gains were found for chromosome 1q, 7, 8q, 13 and 20 and losses were mostly
found for 1p, 4, 8p, 14, 15, 17p, 18, 21 and 22. Data analysis demonstrated that loss of chro-
mosome 4 is linked to a worse prognosis in our patients series. Besides these alterations, two
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interesting small regions of overlap were identified, which could be associated with disease
recurrence. Gain of the 16p13.3 locus (including the RNA binding protein, fox-1 homolog
gene, RBFOX1) was linked with a worse recurrence-free survival in our patient cohort. On the
other hand, loss ofRBFOX1was only found in patients without disease recurrence. Most
interestingly, above mentioned characteristics were also found in stage II patients, for whom
there is a high medical need for the identification of new prognostic biomarkers.
Conclusions
In conclusion, copy number variation of the 16p13.3 locus seems to be an important param-
eter for prediction of disease recurrence in colon cancer.
Introduction
With one million new cases of colorectal cancer (CRC) diagnosed annually in the world, CRC
is the third most commonly diagnosed cancer in the Western world and the second leading
cause of cancer-related deaths in both males and females (9% of all cancers) [1]. One of the
challenges in CRC is to obtain a decrease in death rate by the implementation of screening pro-
grams leading to early detection and treatment of pre-cancerous lesions [2]. Therapeutic deci-
sions are based on a staging system describing tumour extent, presence or absence of lymph
node involvement and distant metastasis (TNM classification) [3]. Early stage CRC can be
cured by surgery alone. The benefit of adjuvant chemotherapy has been most clearly demon-
strated in stage III, whereas benefit in stage II disease remains controversial [3–5]. Nowadays
stage III patients are probably overtreated: all patients receive chemotherapy while about half
of the patients did not experience recurrence before the introduction of adjuvant treatment [6].
On the other hand, stage II patients are probably undertreated, since a substantial number of
them will develop recurrent disease. Identification of high risk stage II patients who will benefit
from adjuvant chemotherapy is highly needed but has thus far been proven difficult to demon-
strate in clinical trials. The use of adjuvant therapy in stage II patients is based on a risk assess-
ment evaluating a.o. microsatellite (MS) status, lymphovascular and perineural invasion,
tumour differentiation and number of examined lymph nodes [6].
There is a need for the identification of additional (bio)markers for the prediction of relapse
in this subgroup of patients. This will hopefully lead to the identification of patients that might
benefit from adjuvant chemotherapy [3].
Recently, much progress has been made in the understanding of colorectal tumour biology.
The histological sequence of colorectal carcinogenesis is characterized by several different
genetic and epigenetic alterations [7,8], such as inactivating APCmutations in familial adeno-
matous polyposis (FAP) or the loss of function of the mismatch repair genes in hereditary non-
polyposis colorectal cancer (HNPCC) [9,10]. In 1990, Fearon et al. suggested a cascade of
mutations in different genes which is considered as the classical or chromosomal instability
(CIN) pathway [7]. The first event in the early stages of a colorectal tumour is APC inactiva-
tion, followed over time by additional mutations of the KRAS and TP53 genes, as well as dele-
tions of chromosome 18q [7,11]. Most of the sporadic CRCs are characterized by those
alterations and are localized in the left side of the colon. Besides this, two other pathways,
involved in the etiology of CRC have been identified. Fifteen percent of sporadic CRCs and
95% of the HNPCC syndromes were shown to carry alterations in the microsatellite instability
(MSI) pathway [10]. Finally, 20–30% of CRC have alterations of the serrated pathway, often
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presenting with a CpG-island methylated phenotype (CIMP) and/or methylation of the
MGMT gene [12,13]. These (epi)genetic alterations can influence the course of the disease and
thereby the outcome of the patients.
Another form of genetic alterations present in colorectal tumours are DNA copy number
alterations (CNAs), which have already been studied in colon cancer, nevertheless without any
consensus [14–17]. Due to the genomic instability of tumours, these CNAs are often present in
tumours and represent potential new biomarkers for the prediction of disease recurrence.
In this study, CNAs were analysed in a large panel of colon cancer patients in different
stages of disease with the aim to evaluate whether specific CNAs relate to patient outcome.
Materials and Methods
Patients and clinical data
A series of 159 primary colon adenocarcinoma resections were examined, prospectively col-
lected between 2004 and 2012 from the department of Gastro-intestinal Surgery of the Ghent
University Hospital in Belgium. The patients were followed until date of death or until clinical
data cut-off (March 2014). The location of the tumour in the colon was designated as right for
tumours located in the caecum, ascending colon and proximal half of the transverse colon.
The location was designated as left when the tumour was located in the distal half of the trans-
verse colon, descending colon and sigmoid. Analyses were performed within each tumor
stage, counting from the date of diagnosis to relapse or date of last follow-up for disease recur-
rence (every stage without stage IV) and death or last follow-up for overall survival (all stages
together). Whenever a correlation between survival and a certain marker was investigated over
all tumour stages together, the relapsed patients were counted as stage IV patients and for these
patients survival in this specific analysis was counted from the date of diagnosis of relapse.
Patients that were treated with adjuvant chemotherapy either received 5FU according to
modified de Gramont (specifically stage II patients) or modified FOLFOX 6 (stage III patients)
during 6 months. Four patients were treated in a clinical trial and may have received additional
biological agents. Stage IV patients were treated with a variety of consecutive palliative
regimens.
A written informed consent for participation was obtained from every patient. The study
was approved by the commission for medical ethics of the Ghent University Hospital (Belgian
registration number: B67020096625). Clinical data were retrieved from the medical files.
Tissue samples
A pathologist, prior to formalin fixation, sampled both primary tumour and macroscopic nor-
mal tissues from resection specimens. Normal tissue was taken as far away as possible from the
tumour in the same resection specimen. All samples were fresh frozen within a maximum of
30 minutes after surgical resection and stored at -80°C. A pathologist scored all tumour sam-
ples for tumour cell content on haematoxylin/eosin stained cryosections. Finally, 93 of 159
tumour samples containing at least 50% tumour cells were retained.
KRASmutation and MSI phenotype
All 159 tumour samples were profiled for the presence of seven somatic KRASmutations in
codon 12 and 13 (12ALA, 12ASP, 12VAL, 12CYS, 12SER, 12ARG and 13ASP) using the
Therascreen KRAS RGQ PCR kit (Qiagen) on formalin-fixed paraffin-embedded (FFPE)
tumour tissue (analysis under ISO15189 accreditation). Other RASmutations were not investi-
gated. The MS status of all 159 tumour samples was analysed by fragment analysis on the
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ABI3130xl genetic analyser (Applied Biosystems) using the GeneMapper software 4 (Applied
Biosystems). BAT25, BAT26, D2S123, D17S250, NR21, D18S55, NR24 and NR27 are the eight
investigated repeat markers. Tumours were classified as MSI when instability of 25% of the
markers was observed. The MSI patients could be divided into two groups, MSI-high and
MSI-low, according to the number of aberrant markers. However, the numbers were too low
for proper statistical analysis. In situations where the distinction was made, it is disclosed in
the text.
DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen) according to the man-
ufacturer’s instructions. The quality and quantity of the DNA samples were measured with a
NanoDrop ND-1000 instrument (Thermo Scientific).
Array comparative genomic hybridization
Copy number alterations were studied by oligo-based array-CGH on the tumour specimens
with at least 50% tumour cells. Specimens with less tumour cells could bias the results. The
samples were profiled on a Custom SurePrint G3 Human CGHMicroarray, 4x180K (G4125A,
Agilent Technologies). The DNA of the colon tumour samples was labeled with the fluorescent
dye Cy3 (Perkin Elmer) and the same amount of commercially available reference male and
female genomic DNA (Kreatech) was labeled with Cy5 (Perkin Elmer). Further processing was
performed according to the manufacturer’s instructions (Agilent Technologies). Fluorescence
intensities were measured using an Agilent scanner (G2505C, Agilent Technologies). Data
were extracted using the Feature Extraction v10.1.1.1 software program (Agilent Technologies)
and further processed with arrayCGHbase [18]. The cut-off values for gained and lost segments
were 0.33 and -0.33 respectively. Aberrations that were present in more than 10 cases in a sepa-
rately screened clinical genetics cohort of 1000 samples were considered as possible constitu-
tional copy number variants (normal copy number alterations) and were excluded from
further analysis. All reported results were manually validated.
Statistics
The statistical environment R (version 2.12.1) was used to execute hierarchical cluster and
heatmap analysis and to construct the graph showing the genome wide frequencies of all
amplifications, gains and losses in all the samples. All other statistical analyses were performed
in SPSS Statistics (version 21). () P<0.05, () p<0.01 and () p<0.001 were considered as
statistically significant in two-tailed tests. Since all the data were normally distributed, ANOVA
was used to compare populations and the Pearson correlation was used for the association
between variables. Survival analyses were performed with the Kaplan-Meier method and the
log rank test. Cox regression analysis was used to calculate hazard ratios.
Results
Clinical characteristics
The clinical data are summarized in S1 Table. All the tumours in this study were primary colon
adenocarcinomas, which were untreated at the time of resection. The patients were predomi-
nantly from Caucasian ethnicity.
In terms of gender association, disease classification, site of the primary tumour, stage, dif-
ferentiation, perineural and lymphovascular invasion, this set of 159 tumours closely resembles
most other reported patient cohorts of sporadic CRC (S1 Table).
The tumours were equally distributed between men and women (57.9% vs 42.1%). The
mucinous variant of adenocarcinoma was diagnosed in 20.1% of the tumours. All patients were
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staged using the AJCC-7 guidelines [19]. The patients were equally distributed over the four
stages, with slightly more patients in stage II (36.5%). Half of the patients (49.7%) received
adjuvant (31.2%) or palliative (18.5%) chemotherapy. At the end of follow-up, 105 patients
(66%) were still alive (S1 Table). Among the 159 patients included in this study, 68 (52.7%)
had an increased carcinoembryonic antigen (CEA) level at time of diagnosis. They had a poorer
prognosis than those with a level below 3.4 ng/μl. Both metastatic or local recurrence and
2-year overall survival (OS) were significantly better for patients with a low CEA level at diag-
nosis (R = 0.260, P = 0.003 for relapse-free survival (RFS); R = 0.271, P = 0.002 for 2-year
OS) (S1 File).
KRASmutation status and MS status and their correlations with the
clinicopathological data
As shown in S1 Table, KRAS-mutations were detected in 51 patients (33.1%). Eight of these
mutations were located in codon 13 (pGly13Asp), all others were located in codon 12 of the
KRAS gene. Among the 159 patients tested for MSI, 87.9% of the colon cancers showed micro-
satellite stability (MSS), two patients (1.3%) were MSI-low and 16 patients (10.7%) were MSI-
high (S1 Table).
In our patient population, we observed a significant correlation between the KRASmutation
and the MS status (R = -0.198, P = 0.017). KRASmutation frequency was higher in MSS
patients than in MSI patients (S2 Table).
We found a significant correlation between the MS status with lymphovascular invasion
(R = -0.181, P = 0.038) and the site of the primary tumour (R = -0.291, P<0.001). We
found MSI at least in one patient in every stage, but mostly in the early stages (two MSI patients
in stage I, seven in stage II and one MSI patient both in stage III and IV) (Table 1). A significant
correlation was found between MS status and tumour classification (R = 0.173, P = 0.034) (S2
Table). This means that patients with MSI usually have a small tumour located in the right
Table 1. Patient characteristics of the patient population with at least 50% of tumour cells (n = 93). An extended table of patient characteristics can be
found in S1 and S2 Tables.
Tumour stage
I (n = 17) II (n = 37) III (n = 20) IV (n = 19)
MS-status MSS 15 (88,2%) 28 (75,7%) 19 (95%) 15 (78,9%)
MSI-low - - - 1 (5,3%)
MSI-high 2 (11,8%) 7 (18,9%) 1 (5%) -
Recurrence Yes 3 (17,6%) 3 (8,1%) 5 (25%) -
No 14 (82,4%) 33 (89,2%) 15 (75%) -
Palliative - - - 19 (100%)
2y-overall survival Death - 5 (13,5%) 5 (25%) 9 (47,4%)
Alive 17 (100%) 32 (86,5%) 15 (75%) 10 (52,6%)
Lymphovascular invasion (Lv) Present 1 (5,9%) 5 (13,5%) 9 (45%) 15 (78,9%)
Absent 14 (82,4%) 30 (81,1%) 8 (40%) 3 (15,8%)
KRAS Wild-type 15 (88,2%) 24 (64,9%) 16 (80%) 13 (68,4%)
Mutant 2 (11,8%) 13 (35,1%) 4 (20%) 6 (31,6%)
16p13.3 locus No alteration 11 (64,7%) 25 (67,6%) 14 (70%) 10 (52,6%)
Loss 4 (23,5%) 9 (24,3%) 4 (20%) 6 (31,6%)
Gain 2 (11,8%) 3 (8,1%) 2 (10%) 3 (15,8%)
doi:10.1371/journal.pone.0131421.t001
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colon, in this cohort most often stage II mucinous adenocarcinoma without lymphovascular
invasion. The colorectal tumours with MSI mostly are KRAS wild type (S2 File).
DNA copy number alterations
After scoring of all tumour samples, 93 samples with at least 50% of tumour cells were retained
for array-CGH analysis. Ninety out of these 93 colon carcinomas showed genomic alterations
(Fig 1). Patients with an increased CEA level had more CNAs than patients with a normal CEA
level at diagnosis (P = 0.023) (Figure A in S3 File). CNAs in our patient cohort were less abun-
dant in MSI patients than in MSS patients, as evaluated by 180K array-CGH (P = 0.016)
(Figure B in S3 File). All the MSI patients had less than ten alterations, whereas the mean num-
ber of alterations for the overall patient cohort is 12.98 (± 0.982). When we looked for alter-
ations in the different tumour stages, we found a higher number of alterations for the MSI
patient only in stage IV, while in the other tumour stages, MSI patients had less CNAs com-
pared to MSS patients (P = 0.003) (Figure C in S3 File). Clustering analysis identified no
statistically significant relationship between cluster groups (based on one or more specific alter-
ation) and any clinical parameter in our database (S1 Fig).
The number of CNAs was divided in three groups after performing a ROC-curve (data not
shown). Two cut-off points were established; the first one at 12 CNAs and the second one at
20 CNAs. In that way, we divided the colon carcinomas in three groups: tumours with less
than 12 alterations, tumours with more than 20 alterations and an intermediate group of
tumours with 12 till 20 alterations.
Survival analysis, calculated according to the number of alterations, revealed a shorter
2-year OS for the patients with more than 20 alterations in all tumour stages together
(P = 0.004) (Fig 2A). In patients with a stage IV tumour, the difference was remarkably larger
(Fig 2B): the mean survival of patients with more than 20 alterations was half of that of patients
with less than 20 alterations (P = 0.015). Unexpectedly, in tumour stages I and II, poorer prog-
nosis was found in the patient group with less than 12 alterations (P = 0.019) (Fig 2C and 2D).
There is also a correlation between the differentiation grade of the tumour and the number
of alterations. Patients, who have well differentiated tumours, had less than 12 CNAs, overall
and for every stage separately. Patients with poorly differentiated tumours and with tumours
Fig 1. Frequency of DNA copy number alterations of all 93 samples for the whole genome.Gains are represented in blue, losses in red.
doi:10.1371/journal.pone.0131421.g001
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carrying more than 20 CNAs, had a worse 2-year OS and specifically when we only compare
stage IV patients (P = 0.006 and P = 0.010 respectively) (S2 Fig).
Array comparative genomic hybridization (array-CGH) analysis showed that the most fre-
quent CNAs in colon carcinomas were gains of chromosomes 1q, 7, 8q, 13, 20 and 20q and
losses of chromosomes 1p, 4, 8p, 14, 15, 17p, 18, 21 and 22 (Fig 1). We also found the presence
of multiple isochromosomes in our samples for chromosomes 1, 5 and 8 (respectively in 5.4%,
5.4% and 7.5% of our patients). Loss of chromosome 4 was significantly linked to a shorter RFS
Fig 2. Kaplan Meier survival curves showing the number of CNAs and the overall survival. (A) For all
stages, **P = 0,004; (B) for stage IV, *P = 0,015; (C) for stage I, *P = 0,019 and (D) for stage II, *P = 0,019.
In the survival curve three groups can be distinguished; the group with less than twelve alterations (blue), the
group with twelve untill twenty alterations (green) and the group with more than twenty alterations (red).
doi:10.1371/journal.pone.0131421.g002
Fig 3. Kaplan Meier survival curves represented a worse prognosis for patients with loss of chromosome 4. Loss of chromosome 4 is linked with a
shorter RFS, ***P<0,001 (A) and a smaller 2-year OS, **P = 0,002 (B). Patients without an alteration of chromosome 4 are presented in green, those with
loss of chromosome 4 in blue.
doi:10.1371/journal.pone.0131421.g003
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(mean RFS is 241.7 weeks for patients with a loss of chromosome 4 and 433.96 weeks for
patients without chromosome 4 loss, P<0.001) (Fig 3A). Loss of chromosome 1, 3, 4 and
9 were linked to a shorter 2-year OS (respectively P = 0.053, P = 0.005, P = 0.002 and
P = 0.069) (Fig 3B and Figures A-C in S4 File). Gain of chromosome 7 and 20 was shown to be
significantly linked with a better 2-year OS (respectively P = 0.048 and P = 0.035) (Figures
D-E in S4 File).
Chromosome 16p13.3 alteration
Locus 16p13.3 was found to be a recurrent alteration, as it is present in 35% of our patient
cohort of 93 patients. Eight patients showed gain of the distal part of this locus and 24 patients
showed a loss with the most recurrent smallest region of overlap (SRO) from 6.5 till 7 Mb.
Eight patients presented with a homozygous deletion. The SRO comprises exon 3 and 4 of the
RBFOX1 gene (6–7Mb). Copy number variant profiles of the normal tissue of the eight homo-
zygous cases were evaluated to exclude a constitutional copy number variant. These results
showed that the homozygous deletions were not constitutional copy number variants, but were
somatically acquired alterations (S3 Fig). More than 70 genes, such as CREBBP,MIR1225,
RAB40C and RAB26, are located in the distal part of the 16p13.3 locus. The latter two genes are
members of the RAS oncogene family, which plays an important role in colon carcinogenesis.
In general, patients without 16p13.3 alterations exhibit less CNAs (R = -0.430, P<0.001).
This applies for all tumour stages (Fig 4A) as well as for every tumour stage separately (data
not shown).
In stage IV tumours, a significant correlation was found between the presence of the
16p13.3 alteration (gain or loss) and the tumour in the right colon (R = -0.384, P = 0.036). In
all other tumour stages, this finding could not be confirmed, even not when all stages were con-
sidered together.
No correlation could be found between the 2-year OS and the presence of a 16p13.3 alter-
ation (Figures A-D in S5 File). However, in the metastatic group, a trend was present (Figure E
in S5 File). Patients who exhibited RBFOX1 loss, showed a worse 2-year OS than patients with-
out this deletion (P = 0.393).
Finally, a significant correlation was shown in all tumour stages between the presence of a
16p13.3 alteration and the RFS (Fig 4B and Figure A in S6 File). When a gain of 16p13.3 was
Fig 4. Gain of 16p13.3 is linked with a worse prognosis. (A) The relation of alteration of the 16p13.3 locus
and the number of CNA in the corresponding patient for all tumour stages, R = -0,430 and ***P<0,001. (B)
Kaplan Meier survival curve showing a worse prognosis for patients with a gain of the 16p13.3 locus over all
tumour stages, **P = 0,010. Gains are represented in green, losses in blue and patients without an alteration
are represented in red.
doi:10.1371/journal.pone.0131421.g004
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present, the prognosis of these patients over all tumour stages was worse than the prognosis
for patients without a 16p13.3 alteration or with a loss of the RBFOX1 gene (HR = 5.018,
P = 0.020). When the same analysis was done for each tumour stage separately, a borderline
significant correlation between the 16p13.3 alteration and disease recurrence was only observed
in stage II tumours (P = 0.022) (Figures B-D in S6 File). None of the patients who had a loss of
the RBFOX1 gene, suffered from a local or metastatic recurrence. On the contrary, patients
without an alteration or with a gain in 16p13.3 had a higher risk of recurrence. The log-rank
test for recurrence in stage II tumours showed a stronger significant correlation for gain of
16p13.3 and time of recurrence (P = 0.008), with a mean time to recurrence of 166 weeks for
patients with a gain of 16p13.3 and 443 weeks for patients without a 16p13.3 alteration
(Figure E in S6 File).
Discussion
The patient characteristics in this study largely correspond to those reported in literature.
Some previously reported findings could however not be validated in this study, like a better
prognosis for patients with MSI-high tumours as described by Gryfe and co-workers [20].
Colon tumours with a KRASmutation are less likely to present microsatellite instability. The
correlation between KRASmutation and MS status has already been shown in previous studies
and complicates the use of this marker in relation to prognosis [21–23].
This could be partly due to the fact that a real distinction of the MSI tumours in MSI-high
and MSI-low could not be made. The association of MSI tumours with the histology of mucin-
ous adenocarcinomas, which was described before, was confirmed in our patient population
[24].
Our study questioned whether copy number alterations could be used as a prognostic
marker for prediction of recurrence of colon cancer, especially in the stage II tumours. Using
array-CGH analysis, we have identified recurrent CNAs among patients with colon carcinoma
with different stages and clinical characteristics. The strengths of our study are the high num-
ber of patients and the integration of clinicopathological characteristics. Another strength is
that we limited the study to colon cancer, because it has been suggested before that the large
discrepancy in published studies is due to the fact that colon and rectal tumours were studied
together [25]. In our study, 97% of the colon tumour samples possess genomic alterations. The
fact that the number of CNAs is higher in stage II MSS tumours compared to MSI tumours has
been suggested before and was validated by Brosens et al. [14]. Nakao and coworkers did also
found a higher frequency of copy number alterations in the patients with MSS towards MSI-H
(20% and 5% respectively). This was also true for gains, losses, amplifications and deletions
separate [26]. Also the group of Xie found a lower CNA prevalence in MSI colorectal tumours
than in MSS tumours [27]. The lower number of CNAs in MSI tumours could be an explana-
tion for the better outcome of patients with an MSI tumour [20]. Our results confirm that
patients with stage II tumours, and more specifically with pT3N0 tumours exhibiting high-fre-
quency MSI, have a better prognosis. Their prognosis seems to be worse when treated with
adjuvant chemotherapy based on 5-FU [28].
Gain of chromosome 13 and 20 and loss of chromosome 18 are the most common genomic
alterations in colon cancer and those findings were confirmed in our study [29]. In addition,
other recurrent gains and losses of whole-chromosomes were found. Gains on 1q, 7, 8q, 13, 20
and 20q and losses on 1p, 4, 8p, 14, 15, 17p, 18, 21 and 22 were mostly found. The occurrences
of these CNAs are in agreement with reported data, but they were never reported all together
in one study [15–17,25,30,31]. Loss of chromosome 1p and gain of chromosome 1q is most
probably leading to the formation of an isochromosome, which is present in 5% of our patient
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population. In literature, there is very little information on formation of isochromosomes in
CRC cell lines and even less in patient samples [15,32]. More information about the functional-
ity of this isochromosome formation might be found by extending the patient cohort.
Statistical analysis showed that loss of chromosomes 1, 3, 4 and 9 was linked with a shorter
survival. On the other hand, gain of chromosomes 7 and 20 is associated with a better 2-year OS.
Moreover, we found a strong significant association for the loss of chromosome 4 and disease
recurrence. Previous studies have shown, both by karyotyping and by meta-analysis of CGH
studies, that loss of chromosome 4 is associated with poor clinical outcome [15,33]. More specifi-
cally, in stage II colon cancer patients, loss of chromosome 4q has already been associated with
disease relapse [14]. Loss of chromosome 4 thus seems to be an important event in the etiology
of colon cancer and could be used as a prognostic marker for recurrence in this disease.
Tumour genomes often possess many subchromosomal and focal alterations next to the
alterations of complete chromosomes and chromosome arms [34,35]. The array-CGH data in
this study revealed a recurrent altered locus, 16p13.3, which contains the RBFOX1 (RNA bind-
ing protein, fox-1 homolog) gene. This locus has not been reported as recurrent alteration with
a clear role in the outcome in other array-CGH studies with an acceptable amount of patients
with CRC [14–17,25,32,33]. Just a few studies have mentioned genetic alterations on 16p13.3
in CRC [27,30,31]. Our results confirm the latter studies. In our study, two SROs in this locus
were linked with important clinical parameters. Gain of the distal 5Mb part of the locus was
found in 9% of patients in this study. Loss of exon 3 and 4 of the RBFOX1 gene was present in
26% of our patients, with the presence of a homozygous deletion of RBFOX1 in one third of
them. To rule out the possibility of a constitutional copy number variant, normal tissue was
tested and found to be normal. Therefore, the 16p13.3 alteration can be classified as a somatic
variant, only present in tumor cells.
Patients with a 16p13.3 alteration were found to exhibit more CNAs than patients without
an alteration of the 16p13.3 locus. This holds for all tumour stages together as well as for each
tumour stage separately. A gain in the 16p13.3 locus was associated with a worse RFS for all the
stages together as well as for stage II tumours separately, which is a very interesting finding
because of the high clinical need of new prognostic markers in stage II colon cancer. In differ-
ent solid tumour types, like breast, lung, hepatocellular and pancreatic cancer gain of 16p13.3
was associated with late stage disease, worse survival and poor differentiation and a late stage
disease [36–39]. Different genes located on the 16p13.3 locus were hypothesized to be impli-
cated in the poor prognosis: in lung cancer TSC2 was brought forward, in pancreatic cancer
PDPK1 [37,39]. The 16p13.3 locus bears a total of 167 known protein-coding genes of which
AXIN1, RAB40C and RAB26 are important genes in CRC. It had already been shown that
AXIN1 was mutated in colorectal cancers and wild-type can induce apoptosis in colorectal can-
cer cells [40]. The RBFOX1 gene is also located in this region. Only few previous publications
considering this gene in CRC were found. One specifically cites a high prevalence in a Bangla-
deshi population with early stage CRC [41]. Correlation with outcome was not investigated in
this small patient group. Deletion of RBFOX1 was also present in a significant proportion of
CRC (106/419) in The Cancer Genome Atlas dataset [42].
Andersen et al. described a frequent loss, including homozygous loss, of the RBFOX1 gene,
associated with a poor clinical outcome in colon cancer [30]. We found a link between gain of
the 16p13.3 locus and worse RFS. Moreover, no patients carrying a somatically acquired
RBFOX1 deletion showed a local or metastatic recurrence. It seems unlikely that an association
between recurrence and loss of RBFOX1 would be found, even after a longer follow-up. More-
over, the number of losses of RBFOX1 is much higher than the number of gains of the 16p13.3
locus. RBFOX1 alterations were also found to be associated with other diseases, like non-small-
cell lung cancer, refractive error of the eye, mental disorders and neurodevelopmental disorders
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[43–46]. In neurodevelopmental and neuropsychiatric disorders losses of the same exons of
RBFOX1 were found [47]. Single nucleotide polymorphisms were found in RBFOX1 in the
region proximal to our SRO in colorectal adenomas [48]. The exact role of RBFOX1 in diseases
however, remains unclear, including its expression in the colon [41]. At present, it is only
known that the RBFOX1 gene codes for a tissue-specific alternative splicing protein [49,50].
Very little is known about the expression or role of RBFOX1 in the intestine. Studies with
immunohistochemistry have confirmed that RBFOX1 is expressed at low levels in normal gut
tissues and that expression is often lost in CRC [41]. Functionally, loss of RBFOX1 activity may
lead to aberrations in the splicing of a significant number of genes, generating diverse func-
tional products that vary from those found in normal tissue. Alternative splicing is a key feature
of cancer. RBFOX1 encodes a ribonucleoprotein motif that is highly conserved among RNA-
binding proteins; it binds to the C-terminus of ataxin-2 and regulates alternative splicing of tis-
sue-specific exons by binding to the hexanucleotide UGCAUG [51,52]. This could suggest an
important basic function in development and differentiation for RBFOX1 [51,53].
Conclusions
In conclusion, the present array-CGH study was performed on a large and unbiased patient
population consisting of different tumour stages and with a sufficiently high number of recur-
rences and deaths in all tumour stages. We could confirm that loss of chromosome 4 is linked
with a worse prognosis in colon cancer. We identified gain of the 16p13.3 locus and loss of the
RBFOX1 gene as candidate biomarkers to predict recurrence in colon cancer; especially in
stage II tumours where there is a high medical need for new prognostic markers. More interest-
ingly, loss of RBFOX1 is a marker excluding disease recurrence in colon cancer. Further study
is needed to validate these results and to reveal the mechanisms by which these genomic alter-
ations may be involved in colon carcinogenesis.
Supporting Information
S1 Fig. Heatmap of cluster analyses of the CNAs of the chromosomes and chromosome
arms and the four different stages of colon cancer. Tumours are displayed as columns,
grouped by the different stages of colon cancer as indicated by four different colours (green,
blue, red and yellow). Chromosomes and chromosome arms used for this clustering are dis-
played as rows. As indicated in the color key; red blocks are losses and blue are gains for a full
chromosome or chromosome arm.
(TIF)
S2 Fig. Boxplot for overall survival (OS) in weeks grouped by the number of copy number
alterations (CNAs) and the differentiation grade (moderate, poor, well or non-differenti-
ated). In blue the patients with less than 12 CNAs, in green from 12 till 20 CNAs and in yellow
the patients with more than 20 alterations.
(TIF)
S3 Fig. DNA copy number profiles of the RBFOX1 gene. DNA copy number profiles are
shown for tumour (at the top) and normal (at the bottom) tissue from the same patient. There
is a clear homozygous deletion in the RBFOX1 gene in the tumour sample (red) and no alter-
ation at all in the profile of the normal tissue.
(TIF)
S1 File. Boxplots for recurrence free survival (Figure A) and 2-year overall survival
(Figure B) in weeks grouped by CEA level at diagnosis. Tumour samples were categorized by
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their CEA level at diagnosis (more or less than 3,4ng/μl).
(TIF)
S2 File. Effect of microsatellite status. Tumour stage (Figure A) and lymphovascular invasion
(Figure B) for microsatellite stable (MSS) versus instability (MSI) patients with colon cancer.
(TIF)
S3 File. Boxplots for copy number alterations (CNA) grouped by CEA level at diagnosis
(Figure A) and MS status (Figure B). The CNAs are also grouped by MS status and tumour
stage together (Figure C); with the MSS patients in blue and the MSI ones in green.
(TIF)
S4 File. Kaplan-Meier survival curves according to the overall survival for different chro-
mosome alterations. (Figure A) 2-year OS and chromosome 1 loss (blue = loss, green = no
alteration); (Figure B) 2-year OS and chromosome 3 alteration (blue = loss, green = no
alteration, yellow = gain); (Figure C) 2-year OS and chromosome 9 alteration (blue = loss,
green = no alteration, yellow = gain); (Figure D) 2-year OS and chromosome 7 gain (blue = no
alteration, green = gain); (Figure E) OS and chromosome 20 gain (blue = no alteration,
green = gain).
(TIF)
S5 File. 2-year overall survival (OS) curves estimated by the Kaplan-Meier method for all
stages together (Figure A), stage I (Figure B), stage II (Figure C), stage III (Figure D) and
stage IV (Figure E) in colon cancer comparing with an alteration in the 16p13.3 locus. In
blue, patients with a loss, in green, patients with a gain and in yellow patients without an alter-
ation in the 16p13.3 locus.
(TIF)
S6 File. Recurrence free survival in association with the 16p13.3 locus. (Figure A) Boxplot
for recurrence free survival in colon cancer and an alteration in the 16p13.3 locus (loss, gain or
no alteration). Recurrence free survival (RFS) curves estimated by the Kaplan-Meier method
for stage I (Figure B), stage II (Figure C), stage III (Figure D) and stage IV (Figure E) in colon
cancer comparing with an alteration in the 16p13.3 locus. In blue, patients with a loss, in green,
patients with a gain and in yellow patients without an alteration in the 16p13.3 locus.
(TIF)
S1 Table. Clinicopathological data for 159 patients with colon cancer (tissues: colorectal
tumour n = 159 and normal n = 159).
(PDF)
S2 Table. Pearson correlations showing the relationships between the different clinico-
pathological characteristics (n = 159).
(PDF)
Author Contributions
Conceived and designed the experiments: EMMDMNVR KG SL. Performed the experiments:
EM TVL. Analyzed the data: EM AF NVR. Contributed reagents/materials/analysis tools: AF
KCWC YVN PP. Wrote the paper: EM KDR NVR KG SL. Scored all tumour samples and gave
access to all pathological data: LF.
Focus on 16p13.3 Locus in Colon Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131421 July 29, 2015 12 / 15
References
1. Siegel RL, Ward EM, Jemal A (2012) Trends in Colorectal Cancer Incidence Rates in the United States
by Tumor Location and Stage, 1992–2008. Cancer Epidemiology Biomarkers & Prevention 21: 411–
416.
2. Phillips KA, Liang SY, Ladabaum U, Haas J, Kerlikowske K, et al. (2007) Trends in colonoscopy for
colorectal cancer screening. Medical Care 45: 160–167. PMID: 17224779
3. McGee MF, Benson AB (2014) Adjuvant Chemotherapy for Stage II Colon Cancer: Everyone Still
Needs a Tailor. Annals of Surgical Oncology.
4. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, et al. (2009) Improved Overall Survival With Oxali-
platin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the
MOSAIC Trial. Journal of Clinical Oncology 27: 3109–3116. doi: 10.1200/JCO.2008.20.6771 PMID:
19451431
5. Andre T, Sargent D, Tabernero J, O'Connell M, Buyse M, et al. (2006) Current issues in adjuvant treat-
ment of stage II colon cancer. Annals of Surgical Oncology 13: 887–898. PMID: 16614880
6. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. (2013) Localized Colon Cancer, Version
3.2013 Featured Updates to the NCCNGuidelines. Journal of the National Comprehensive Cancer
Network 11: 519–528. PMID: 23667203
7. Fearon ER, Vogelstein B (1990) A Genetic Model for Colorectal Tumorigenesis. Cell 61: 759–767.
PMID: 2188735
8. Wong JJL, Hawkins NJ, Ward RL (2007) Colorectal cancer: a model for epigenetic tumorigenesis. Gut
56: 140–148. PMID: 16840508
9. Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, et al. (1990) Genetic Changes and Histopatho-
logical Types in Colorectal Tumors from Patients with Familial Adenomatous Polyposis. Cancer
Research 50: 7166–7173. PMID: 1977514
10. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, et al. (1996) Microsatellite instability
and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12: 2641–2649. PMID: 8700523
11. van den Berg FM, Tigges AJ, Schipper ME, den Hartog-Jager FC, KroesWG, et al. (1989) Expression
of the nuclear oncogene p53 in colon tumours. Journal of Pathology 157: 193–199. PMID: 2926561
12. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, et al. (1999) Identification of differentially methylated
sequences in colorectal cancer by methylated CpG island amplification. Cancer Research 59: 2307–
2312. PMID: 10344734
13. Hawkins NJ, Lee JHF, Wong JJL, Kwok CT, Ward RL, et al. (2009) MGMTmethylation is associated
primarily with the germline C > T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.
Modern Pathology 22: 1588–1599. doi: 10.1038/modpathol.2009.130 PMID: 19734844
14. Brosens RPM, Belt EJTH, Haan JC, Buffart TE, Carvalho B, et al. (2011) Deletion of chromosome 4q
predicts outcome in Stage II colon cancer patients. Cellular Oncology 34: 215–223.
15. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, et al. (2006) The order of genetic events
associated with colorectal cancer progression inferred frommeta-analysis of copy number changes.
Genes Chromosomes & Cancer 45: 31–41.
16. Loo LWM, Tiirikainen M, Cheng I, Lum-Jones A, Seifried A, et al. (2013) Integrated analysis of genome-
wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phe-
notype-negative colon cancer. Genes Chromosomes & Cancer 52: 450–466.
17. Sawada T, Yamamoto E, Suzuki H, Nojima M, Maruyama R, et al. (2013) Association between genomic
alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic
hybridization. Genes Chromosomes & Cancer 52: 140–149.
18. Menten B, Pattyn F, De Preter K, Robbrecht P, Michels E, et al. (2005) arrayCGHbase: an analysis plat-
form for comparative genomic hybridization microarrays. Bmc Bioinformatics 6.
19. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th Edition of the AJCC
Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology 17: 1471–1474. doi: 10.
1245/s10434-010-0985-4 PMID: 20180029
20. Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, et al. (2000) Tumor microsatellite instability and
clinical outcome in young patients with colorectal cancer. New England Journal of Medicine 342: 69–
77. PMID: 10631274
21. Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, et al. (2010) KRASMutation and Microsatellite
Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorec-
tal Cancer. Annals of Surgical Oncology 17: 416–424. doi: 10.1245/s10434-009-0713-0 PMID:
19813061
Focus on 16p13.3 Locus in Colon Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131421 July 29, 2015 13 / 15
22. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. (2010) Prognostic Role of KRAS and BRAF in
Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC
40993, SAKK 60–00 Trial. Journal of Clinical Oncology 28: 466–474. doi: 10.1200/JCO.2009.23.3452
PMID: 20008640
23. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, et al. (2011) Value of Mismatch Repair,
KRAS, and BRAFMutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal
Cancer. Journal of Clinical Oncology 29: 1261–1270. doi: 10.1200/JCO.2010.30.1366 PMID:
21383284
24. Verhulst J, Ferdinande L, Demetter P, CeelenW (2012) Mucinous subtype as prognostic factor in colo-
rectal cancer: a systematic review and meta-analysis. Journal of Clinical Pathology 65: 381–388. doi:
10.1136/jclinpath-2011-200340 PMID: 22259177
25. Shi ZZ, Zhang YM, Shang L, Hao JJ, Zhang TT, et al. (2012) Genomic profiling of rectal adenoma and
carcinoma by array-based comparative genomic hybridization. Bmc Medical Genomics 5.
26. Nakao K, Mehta KR, Moore DH, Jain AN, Lafuente A, et al. (2004) High-resolution analysis of DNA
copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carci-
nogenesis 25: 1345–1357. PMID: 15001537
27. Xie T, d' Ario G, Lamb JR, Martin E, Wang K, et al. (2012) A Comprehensive Characterization of
Genome-Wide Copy Number Aberrations in Colorectal Cancer Reveals Novel Oncogenes and Pat-
terns of Alterations. Plos One 7.
28. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. (2003) Tumor microsatellite-instabil-
ity status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
New England Journal of Medicine 349: 247–257. PMID: 12867608
29. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, et al. (2009) Multiple putative oncogenes at
the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58:
79–89. doi: 10.1136/gut.2007.143065 PMID: 18829976
30. Andersen CL, Lamy P, Thorsen K, Kjeldsen E, Wikman F, et al. (2011) Frequent genomic loss at
chr16p13.2 is associated with poor prognosis in colorectal cancer. International Journal of Cancer 129:
1848–1858.
31. Krijgsman O, Israeli D, Haan JC, van Essen HF, Smeets SJ, et al. (2012) CGH arrays compared for
DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes & Cancer 51:
344–352.
32. Knutsen T, Padilla-Nash HM, Wangsa D, Barenboim-Stapleton L, Camps J, et al. (2010) Definitive
Molecular Cytogenetic Characterization of 15 Colorectal Cancer Cell Lines. Genes Chromosomes &
Cancer 49: 204–223.
33. Bardi G, Fenger C, Johansson B, Mitelman F, Heim S (2004) Tumor karyotype predicts clinical outcome
in colorectal cancer patients. Journal of Clinical Oncology 22: 2623–2634. PMID: 15226330
34. Brosens RPM, Haan JC, Carvalho B, Rustenburg F, Grabsch H, et al. (2010) Candidate driver genes in
focal chromosomal aberrations of stage II colon cancer. Journal of Pathology 221: 411–424. doi: 10.
1002/path.2724 PMID: 20593488
35. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, et al. (2008) Integrated analysis of homozygous dele-
tions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of
the National Academy of Sciences of the United States of America 105: 16224–16229. doi: 10.1073/
pnas.0808041105 PMID: 18852474
36. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, et al. (2009) 3-Phosphoinositide-Dependent Kinase 1
Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma.
Cancer Research 69: 6299–6306. doi: 10.1158/0008-5472.CAN-09-0820 PMID: 19602588
37. Shen H, Zhu Y, Wu YJ, Qiu HR, Shu YQ (2008) Genomic alterations in lung adenocarcinomas detected
by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet-
ics and Cytogenetics 181: 100–107. doi: 10.1016/j.cancergencyto.2007.11.012 PMID: 18295661
38. Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, et al. (2005) Genetic profile of hepatocellular
carcinoma revealed by array-based comparative genomic hybridization: Identification of genetic indica-
tors to predict patient outcome. Journal of Hepatology 43: 863–874. PMID: 16139920
39. Choucair KA, Guerard KP, Ejdelman J, Chevalier S, Yoshimoto M, et al. (2012) The 16p13.3 (PDPK1)
Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology 5:
453–460. PMID: 23401739
40. Segditsas S, Tomlinson I (2006) Colorectal cancer and genetic alterations in theWnt pathway. Onco-
gene 25: 7531–7537. PMID: 17143297
Focus on 16p13.3 Locus in Colon Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131421 July 29, 2015 14 / 15
41. Sengupta N, Yau C, Sakthianandeswaren A, Mouradov D, Gibbs P, et al. (2013) Analysis of colorectal
cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high preva-
lence of RBFOX1 deletion. Molecular Cancer 12.
42. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, et al. (2012) Comprehensive molecular
characterization of human colon and rectal cancer. Nature 487: 330–337. doi: 10.1038/nature11252
PMID: 22810696
43. Huang YT, Heist RS, Chirieac LR, Lin XH, Skaug V, et al. (2009) Genome-Wide Analysis of Survival in
Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 27: 2660–2667. doi: 10.1200/
JCO.2008.18.7906 PMID: 19414679
44. Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge KD, et al. (2011) Clinically Relevant Single
Gene or Intragenic Deletions Encompassing Critical Neurodevelopmental Genes in Patients With
Developmental Delay, Mental Retardation, and/or Autism Spectrum Disorders. American Journal of
Medical Genetics Part A 155A: 2386–2396. doi: 10.1002/ajmg.a.34177 PMID: 22031302
45. Stambolian D, Wojciechowski R, Oexle K, Pirastu M, Li XH, et al. (2013) Meta-analysis of genome-wide
association studies in five cohorts reveals common variants in RBFOX1, a regulator of tissue-specific
splicing, associated with refractive error. Human Molecular Genetics 22: 2754–2764. doi: 10.1093/
hmg/ddt116 PMID: 23474815
46. Wang KS, Liu XF, Aragam N (2010) A genome-wide meta-analysis identifies novel loci associated with
schizophrenia and bipolar disorder. Schizophrenia Research 124: 192–199. doi: 10.1016/j.schres.
2010.09.002 PMID: 20889312
47. ZhaoWW (2013) Intragenic deletion of RBFOX1 associated with neurodevelopmental/neuropsychiatric
disorders and possibly other clinical presentations. Molecular Cytogenetics 6.
48. Zhou DE, Yang L, Zheng LT, GeWT, Li D, et al. (2013) Exome Capture Sequencing of Adenoma
Reveals Genetic Alterations in Multiple Cellular Pathways at the Early Stage of Colorectal Tumorigene-
sis. Plos One 8.
49. Nakahata S, Kawamoto S (2005) Tissue-dependent isoforms of mammalian Fox-1 homologs are asso-
ciated with tissue-specific splicing activities. Nucleic Acids Research 33: 2078–2089. PMID: 15824060
50. Auweter SD, Fasan R, Reymond L, Underwood JG, Black DL, et al. (2006) Molecular basis of RNA rec-
ognition by the human alternative splicing factor Fox-1. Embo Journal 25: 163–173. PMID: 16362037
51. Shibata H, Huynh DP, Pulst SM (2000) A novel protein with RNA-binding motifs interacts with ataxin-2.
Human Molecular Genetics 9: 1303–1313. PMID: 10814712
52. Underwood JG, Boutz PL, Dougherty JD, Stoilov P, Black DL (2005) Homologues of the Caenorhabdi-
tis elegans Fox-1 protein are neuronal splicing regulators in mammals. Molecular and Cellular Biology
25: 10005–10016. PMID: 16260614
53. Kiehl TR, Shibata H, Vo T, Huynh DP, Pulst SM (2001) Identification and expression of a mouse ortho-
log of A2BP1. Mammalian Genome 12: 595–601. PMID: 11471052
Focus on 16p13.3 Locus in Colon Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131421 July 29, 2015 15 / 15
